Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Osteosarcoma 14Sarcoma 10Lymphoma 7Dendritic Cell Sarcoma, Interdigitating 7Burkitt Lymphoma 5Lymphoma, Large B-Cell, Diffuse 4Leukemia 4Colorectal Neoplasms 4Stomach Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Gastrointestinal Stromal Tumors 3Central Nervous System Neoplasms 3Carcinoma, Hepatocellular 3Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 2Neoplasms 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Gliosarcoma 2Glioblastoma 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Bile Duct Neoplasms 2Appendiceal Neoplasms 2Vipoma 1

Interventions

Ifosfamide 5Filgrastim 5Doxorubicin 5Gemcitabine 4Docetaxel 4Radiotherapy 3Proton Therapy 3Carboplatin 3regorafenib 2ivosidenib 2enasidenib 2belinostat 2Sunitinib 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Immune Checkpoint Inhibitors 2HhAntag691 2Fluorouracil 2Etoposide 2Epirubicin 2Cyclophosphamide 2Cisplatin 2Chemotherapy, Adjuvant 2Celecoxib 2Bevacizumab 2venetoclax 1toripalimab 1temsirolimus 1tazemetostat 1tanespimycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chondrosarcoma × Leucovorin × Sarcoma × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡